Verghese M W, McConnell R T, Lenhard J M, Hamacher L, Jin S L
Department of Cell Biology, Glaxo Inc. Research Institute, Research Triangle Park, North Carolina 27709, USA.
Mol Pharmacol. 1995 Jun;47(6):1164-71.
Many functions of the immune and inflammatory responses are inhibited by agents that increase intracellular levels of cAMP. Recent investigations have revealed that cAMP levels in inflammatory cells are regulated by cyclic nucleotide phosphodiesterases (PDEs) belonging to the PDE4 family (cAMP-specific PDEs). At least four different genes are known to encode PDE4 isozymes, which are characterized by their selectivity for cAMP over cGMP and their sensitivity to the antidepressant drug rolipram. The aim of our studies was to investigate whether monocytic cells could regulate PDE4 activity and whether certain PDE4 isozymes were expressed preferentially over others. Our results showed that treatment of peripheral blood monocytes or closely related Mono Mac 6 cells with dibutyryl-cAMP or other cAMP-elevating agents transiently increased rolipram-sensitive PDE4 activity 2-3-fold, without concomitant increases in cGMP-inhibited PDE (PDE3) activity. PDE4 activity was predominantly cytosolic, whereas PDE3 activity was localized to the particulate fraction. Our Northern and Western blot studies with reagents recognizing three distinct PDE4 gene products (PDE4A, PDE4B, and PDE4D) revealed that their expression is transcriptionally regulated in monocytic cells. Although none of the three isozymes was detectable under normal culture conditions, all of these were up-regulated when Mono Mac 6 cells were exposed to dibutyryl-cAMP. Distinct differences were observed in their temporal patterns of expression. Endotoxin lipopolysaccharide, a potent monocyte stimulus, also enhanced PDE4 activity in monocytic cells. These data indicate that monocytic cells may express different PDE4 isozymes, depending on their state of activation or differentiation. These isozymes could thus regulate intracellular cAMP levels at various stages of monocyte activation and could thereby be important in limiting the inflammatory response.
免疫和炎症反应的许多功能受到能增加细胞内cAMP水平的药物的抑制。最近的研究表明,炎症细胞中的cAMP水平受属于PDE4家族(cAMP特异性磷酸二酯酶)的环核苷酸磷酸二酯酶(PDEs)调节。已知至少有四个不同的基因编码PDE4同工酶,其特征在于它们对cAMP比对cGMP的选择性以及它们对抗抑郁药咯利普兰的敏感性。我们研究的目的是调查单核细胞是否能调节PDE4活性,以及某些PDE4同工酶是否比其他同工酶更优先表达。我们的结果表明,用二丁酰-cAMP或其他提高cAMP的药物处理外周血单核细胞或密切相关的Mono Mac 6细胞,可使咯利普兰敏感的PDE4活性瞬时增加2-3倍,而cGMP抑制的磷酸二酯酶(PDE3)活性没有相应增加。PDE4活性主要存在于细胞质中,而PDE3活性定位于颗粒部分。我们用识别三种不同PDE4基因产物(PDE4A、PDE4B和PDE4D)的试剂进行的Northern和Western印迹研究表明,它们的表达在单核细胞中受转录调控。虽然在正常培养条件下这三种同工酶均未检测到,但当Mono Mac 6细胞暴露于二丁酰-cAMP时,所有这些同工酶均上调。在它们的表达时间模式上观察到明显差异。内毒素脂多糖是一种有效的单核细胞刺激物,也能增强单核细胞中的PDE4活性。这些数据表明,单核细胞可能根据其激活或分化状态表达不同的PDE4同工酶。因此,这些同工酶可以在单核细胞激活的各个阶段调节细胞内cAMP水平,从而在限制炎症反应中可能起重要作用。